CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The European Regimen Accelerator for Tuberculosis project focuses on developing new combination therapies for tuberculosis. It employs a flexible drug development approach, utilizing advanced preclinical models and artificial intelligence to optimize drug candidates for clinical trials.
The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA.
Since details of these are as yet unavailable, we will implement an agile drug development algorithm that entails profiling and portfolio construction.
Profiling involves characterisation and ranking molecules in preclinical studies comprising in vitro drug combination assays, hollow fiber…
UNIVERSIDAD CARLOS III DE MADRID
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Zaragoza
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Madrid
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
